Royaume-Uni - 356618, > = 98 %(HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

UK-356618 has been used as a specific matrix metalloproteinase 3 (MMP3) inhibitor to study its effect on amitriptyline-induced glial cell line-derived neurotrophic factor (GDNF) mRNA expression and to confirm its influence on amitriptyline-induced zymographic MMP-9 activation in rat C6 astroglial cells.

Biochem/physiol Actions

UK-356,618 is a potent, selective inhibitor of Matrix metalloproteinase MMP3 (stromelysin-1). MMP-3 IC₅₀ = 5.9 nM, selectivity is 140-fold vs MMP-1, -2, -9, and -14.

UK 356618 has the potential to inhibit interleukin (IL)-6-induced cell migration in NCI H446 small cell lung cancer cellsin vitro.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Cytoskeleton & Extracellular Matrix research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle